Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine

By Trivello R.   Chiaramonte M.   Ngatchu T.   Baldo V.   Majori S.   Moschen M.E.   Simoncello I.   Renzulli G.   Naccarato R.  

Vaccine, Vol. 13, Iss. 2, 1995-02 ,pp. : 139-141

Elsevier

Access to resources Recommend Favorite

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

By Van Herck K.   Van Damme P.   Thoelen S.   Meheus A.  

Vaccine, Vol. 16, Iss. 20, 1998-12 ,pp. : 1933-1935

Elsevier

Access to resources Recommend Favorite

Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines

By Coursaget P.   Fritzell B.   Blondeau C.   Saliou P.   Diop-Mar I.  

Vaccine, Vol. 13, Iss. 1, 1995-01 ,pp. : 109-111

Elsevier

Access to resources Recommend Favorite

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

By Ping-Ing L.   Chin-Yun L.   Li-Min H.   Jong-Min C.   Mei-Hwei C.  

Vaccine, Vol. 13, Iss. 17, 1995-12 ,pp. : 1685-1689

Elsevier

Access to resources Recommend Favorite

Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/l seroprotection levels unreliable

By Heijtink R.A.   Schneeberger P.M.   Postma B.   Crombach W.  

Vaccine, Vol. 20, Iss. 23, 2002-07 ,pp. : 2899-2905

Elsevier

Access to resources Recommend Favorite